Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 315

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 315
---
 a change of control (as defined within the note purchase agreement to be events other than a reverse merger) while the Convertible Notes remain outstanding, the Company shall repay the note holders in cash an amount equal to (i) the outstanding principal amount of the Convertible Notes plus any unpaid accrued interest on the original principal, plus (ii) a repayment premium equal to % of the outstanding principal amount of the Convertible Notes.

Maturity date conversion

In the event the Convertible Notes remain outstanding on or following the Maturity Date, the noteholders shall have the option to elect to have the outstanding principal balance of the Convertible Notes and any unpaid accrued interest thereon convert into shares of the Company’s Series B Preferred Stock at a conversion price per share equal to $.

The Convertible Notes were recorded at fair value of $ million upon issuance and were remeasured to the fair value of $ million as of December 31, 2024. The change in the fair value of the Convertible Notes of $ million was recorded within other income (expense), net on the Company’s statement of operations for the year ended December 31, 2024. There was approximately $ million of debt issuance costs incurred in connection with the Convertible Notes. This amount was recognized within other income (expense), net in the Company’s statement of operations during the year ended December 31, 2024.

The future minimum principal payments under the Convertible Notes, if not otherwise converted pursuant to the terms above, as of December 31, 2024 are as follows:

| ​                        
 ​                        
 Years ended December 31, | ​ 
 ​ | ​         
 Principal 
 Payments  |      ​ |
|:-------------------------|:--|:----------|-------:|
| 2025                     | ​ | $         |      — |
| 2026                     | ​ |           | 28,298 |
| Thereafter               | ​ |           |      — |
| Total                    | ​ | $         | 28,298 |

9.Redeemable Convertible Preferred Stock The Company has issued Series A preferred stock and Series B preferred stock, which are collectively referred to as the Preferred Stock. As of December 31, 2024 and 2023, the Company authorized the issuance of 29,723,540shares of Preferred Stock, par value of $ 0.001per share, of which 9,499,999have been designated Series A preferred stock and 20,223,541have been designated Series